Preclinical data shows KRRO-111 achieves over 95% SERPINA1 editing, restoring functional lung protein and reducing toxic liver buildup, potentially initiating regulatory submissions in the first half of 2027.
Preclinical data shows KRRO-111 achieves over 95% SERPINA1 editing, restoring functional lung protein and reducing toxic liver buildup, potentially initiating regulatory submissions in the first half of 2027.